Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Licensing Deals Still Backloaded In 2013, But Biotechs Could Gain Leverage

Executive Summary

An analysis of alliance deals in 2013 shows pharmas’ continued reliance on heavily structured deals, a strategy that has often frustrated biotechs looking to partner. But the appetite for new IPO listings may be giving them more options, provoking competitive deal terms from licensors.

You may also be interested in...



Biopharma M&A In An Era Of Elusive Growth, Capital Triage, and New Competitors

Investor-friendly capital allocation and the rising strength of large biotechs and specialty pharmas have jeopardized Big Pharma’s position of strength in M&A. Analysis by Ernst & Young suggests that industry’s largest companies face unusual challenges – and must adapt to new marketplace realities.

Pharmas Among Biggest Cash Hoarders, Moody’s Finds

A Moody’s report lists seven pharmas among the 50 non-financial companies sitting on the largest piles of cash. These very big war chests hold the preferred currency, particularly for ex-U.S.pharma deal-making.

In 2012, Buyer’s Market Made Alliances Rarer

With little leverage against Big Pharma, some smaller companies are turning away from long-standing partnering strategies. It’s one reason dealmaking slowed considerably in 2012, part of a three-year trend that also highlights increasing reliance on heavily structured partnerships.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel